EvolveImmune Therapeutics Announces Achievement of Preclinical Milestone in Collaboration with AbbVie
· evolveimmune therapeutics
AI Briefing
- EvolveImmune Therapeutics achieves preclinical milestone in collaboration with AbbVie
- Successful nomination of development candidate for next-generation cancer biotherapeutic
- Triggers $18 million milestone payment to EvolveImmune
Advertisement